Lentiviral vectors for cancer immunotherapy and clinical applications
about
RNA Interference in the Age of CRISPR: Will CRISPR Interfere with RNAi?Intratumoral Lentivector-Mediated TGF-β1 Gene Downregulation As a Potent Strategy for Enhancing the Antitumor Effect of Therapy Composed of Cyclophosphamide and Dendritic CellsLentiviral Vector Mediated Claudin1 Silencing Inhibits Epithelial to Mesenchymal Transition in Breast Cancer Cells.Therapeutic Vaccine Strategies against Human Papillomavirus.Antigenically Modified Human Pluripotent Stem Cells Generate Antigen-Presenting Dendritic CellsDevelopment of Endothelial-Specific Single Inducible Lentiviral Vectors for Genetic Engineering of Endothelial Progenitor Cells.Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy.Use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases.Dendritic Cells Cross-Present Immunogenic Lentivector-Encoded Antigen from Transduced Cells to Prime Functional T Cell Immunity.Gene therapy as a potential tool for treating neuroblastoma-a focused review.Pseudotyped murine leukemia virus for schistosome transgenesis: approaches, methods and perspectives.Multiple Sclerosis Gene Therapy with Recombinant Viral Vectors: Overexpression of IL-4, Leukemia Inhibitory Factor, and IL-10 in Wharton's Jelly Stem Cells Used in EAE Mice Model.A biosafety level 2 virology lab for biotechnology undergraduates.Eliminating HIV-1 Packaging Sequences from Lentiviral Vector Proviruses Enhances Safety and Expedites Gene Transfer for Gene Therapy.A novel treatment approach for retinoblastoma by targeting epithelial growth factor receptor expression with a shRNA lentiviral system.Recombination-deletion between homologous cassettes in retrovirus is suppressed via a strategy of degenerate codon substitution.Practical considerations for chimeric antigen receptor design and delivery.Genetic abrogation of immune checkpoints in antigen-specific cytotoxic T-lymphocyte as a potential alternative to blockade immunotherapy.Adeno-associated Virus (AAV) Dual Vector Strategies for Gene Therapy Encoding Large Transgenes.Reprogramming the murine colon cancer microenvironment using lentivectors encoding shRNA against IL-10 as a component of a potent DC-based chemoimmunotherapy.
P2860
Q26765460-827C08F9-F7C3-428B-868A-B3D33455D98AQ33858506-E55B0B65-E7B8-46F1-9C2B-91A503A10B24Q35808662-3A011E51-6247-467D-8D29-824B2E46A8A7Q35826752-3B53C017-F0E1-4B62-8080-2F83F02D53B0Q36168490-413AC788-9B51-442E-9200-5C9D4055C937Q36324274-B9F03E18-A75D-4080-8BA3-7BDCCE971226Q37635491-DB3A0CE1-71A9-4E9D-B105-79DED18E50D1Q38181868-FF1EFC88-ABE0-4A1F-8FE2-89FD6B72C7F6Q38762699-E0C04AF5-30C8-4FA4-BF75-438E4E37649DQ38808728-C3A1C98A-6F76-47AB-A299-6ADB15FDE387Q39211453-7FA4BE2E-6E65-4975-818B-C6BB27F94F6FQ40072578-66F557AA-CB8B-44FE-82D4-E6265AFD9ECEQ40101784-695B1750-42D2-43EB-8E61-769A93FDE25FQ40183063-F1F85603-3003-4B05-AFE5-352590436D7AQ41507784-9E9DFE07-3653-4B4F-BBF6-C4CBCC3B1A2DQ41878298-3255493F-4394-4ED5-B693-AAB061B6D115Q45868559-9ED7DE35-B978-41B0-8F4B-6446ACB8A48EQ52431278-8B2F3B3D-ED8B-4F4E-A3C5-4C868EBAB9CDQ52743732-C61A47B6-2C44-4A15-9096-811163B2AA27Q55515862-1F52816B-E505-4038-8E8E-84AA9156AFAD
P2860
Lentiviral vectors for cancer immunotherapy and clinical applications
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Lentiviral vectors for cancer immunotherapy and clinical applications
@en
type
label
Lentiviral vectors for cancer immunotherapy and clinical applications
@en
prefLabel
Lentiviral vectors for cancer immunotherapy and clinical applications
@en
P2860
P356
P1433
P1476
Lentiviral vectors for cancer immunotherapy and clinical applications
@en
P2093
Noemi Perez-Janices
Therese Liechtenstein
P2860
P304
P356
10.3390/CANCERS5030815
P50
P577
2013-09-01T00:00:00Z